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Abstract
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Objectives: Inflammation contributes to chronic diseases. Lower serum testosterone among men
is associated with less inflammation, yet immune defense is thought to trade-off against
reproduction with androgens adversely affecting immune function. Anti-androgens are effective at
castrate levels of serum testosterone, suggesting serum testosterone may not capture all androgen
activity. The association of two androgen biomarkers with key markers of inflammation was
examined.
Methods: The adjusted association of serum testosterone and androstanediol glucuronide with Creactive protein, white blood cell, granulocyte and lymphocyte count, fibrinogen and hemoglobin,
as a control outcome because testosterone administration raises hemoglobin, were examined in a
nationally representative sample of 1490 US men from NHANES III phase 1 (1988-91) using
multivariable linear regression.
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Results: Serum testosterone and androstanediol glucuronide were weakly correlated (0.13).
Serum testosterone was associated with lower white blood cell count (−0.26*10−9 per standard
deviation, 95% confidence interval (CI) −0.37 to −0.14) and granulocyte count (−0.21*10−9, 95%
CI −0.29 to −0.13) but not with hemoglobin (0.02 g/L, 95% CI −0.89 to 0.92), adjusted for age,
education, race/ethnicity, smoking and alcohol. Similarly adjusted, androstanediol glucuronide
was not associated with white blood cell count (0.10*10−9, 95% CI −0.05 to −0.25), granulocyte
count (0.12*10−9, 95% CI −0.02 to 0.25) or fibrinogen (0.05g/L, 95% CI −0.004 to 0.11), but was
with hemoglobin (0.70g/L, 95% CI 0.07 to 1.32).
Conclusions: Different androgen biomarkers had different associations with inflammatory
markers, highlighting the need to consider several androgen biomarkers. The possibility remains
that androgens may generate inflammatory processes with implications for chronic diseases.
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Non-communicable chronic diseases are increasingly recognized as inflammatory conditions
(Swirski and Nahrendorf, 2013;Tabas and Glass, 2013) potentially reversible by therapies
targeting systemic low-grade inflammation (Tabas and Glass, 2013). Since testicular
extracts were first developed in the 1920s androgens have been known to affect components
of the immune system in animals, such as the size of the thymus (Dougherty,
1952;Korenchevsky et al., 1932). Within a life history framework (Stearns, 2005), fitness is
thought to depend on how well resource allocation is optimized between reproductive
success and survival, with androgens being a potential mechanism driving this allocation
(Folstad and Karter, 1992). Males may gain more fitness (descendants) by concentrating on
reproductive success at the expense of a less well functioning immune system and
potentially shorter lives whilst females may gain more from longevity (Rolff, 2002;Zuk,
2009). Although empirical support for this hypothesis in animals is not comprehensive
(Kotiaho, 2001), it is thought that there are trade-offs between immune defense and
reproductive success (Schroderus et al., 2010), with some evidence that androgens suppress
immunity in animals (Hepworth et al., 2010;Pinto et al., 2010;Sasaki et al., 2013). The
potential relevance of interactions of sex-steroids with the immune system to humans is also
increasingly being recognized (Grossman, 1985;Sakiani et al., 2012).
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Generally women are more vulnerable to auto-immune diseases, with the difference
emerging at puberty, whilst men are more vulnerable to infections (Marriott and HuetHudson, 2006); most markedly at life stages when androgens are higher (Guerra-Silveira
and Abad-Franch, 2013). However, women may be more vulnerable to infectious diseases
where a strong immune response enhances pathogenesis (Guerra-Silveira and Abad-Franch,
2013). These sex-specific patterns of diseases in humans are thought to arise because
estrogens promote a more vigorous immune response which results in greater risk of autoimmune disease as well as a stronger response to infections, whilst androgens are thought to
be immunosuppressive (Cutolo et al., 2004;Schuurs and Verheul, 1990). Correspondingly
androgen deprivation therapy may enhance aspects of immune response (Aragon-Ching et
al., 2007;Morse and McNeel, 2010). The causes of the low-grade systematic inflammation
which characterizes many non-communicable chronic conditions is not fully understood, but
is not thought to be due to autoimmunity (Tabas and Glass, 2013). Instead such
inflammation appears to be a state of immune dysregulation or dysfunction, to which factors
that potentially affect immune function could be relevant. However, the association of
androgens with markers of low-grade systemic inflammation in humans, such as C-reactive
protein (CRP), fibrinogen (Tabas and Glass, 2013) or white cell count (Bonaterra et al.,
2010;Lowe, 2005) is not well established.
Few of the randomized controlled trials (RCTs) of testosterone therapy among men have
reported effects on inflammatory markers. The available evidence from these RCTs
generally shows little effect of testosterone therapy on CRP (Aversa et al., 2010;Frederiksen
et al., 2013;Kapoor et al., 2007;Nakhai-Pour et al., 2007;Ng et al., 2002), white blood cell
count (Kalinchenko et al., 2010) or fibrinogen (Smith et al., 2005), although one RCT
reported testosterone decreased CRP (Kalinchenko et al., 2010) among a subset of men.
Larger observational studies among men usually, but not always, report serum testosterone
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inversely associated with CRP (Gannage-Yared et al., 2011;Haring et al., 2012;Kupelian et
al., 2010;Laaksonen et al., 2003;Nakhai Pour et al., 2007;Zhang et al., 2013), white blood
cell counts and/or its differentials (Brand et al., 2012;Haring et al., 2012;Tang et al., 2007)
and fibrinogen (Bonithon-Kopp et al., 1988;Haring et al., 2012;Yang et al., 1993).
Experimental and observational evidence may differ for a number of reasons: the small size
of most RCTs of testosterone therapy, differences in the action of exogenous and
endogenous testosterone, serum testosterone acting as a marker of health status or serum
testosterone not capturing all androgen activity (Labrie et al., 2009).
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Serum testosterone largely originates from the gonads, and then may act directly via the
androgen receptor, may be metabolized to dihydrotestosterone, which also acts via the
androgen receptor, but with greater potency, or may be metabolized to estrogen (Auchus and
Auchus, 2012). Androgen precursors may also be produced in other parts of the body, such
as the adrenals (Auchus and Auchus, 2012), or androgens may be produced and used locally
without entering the circulation (Labrie, 1991). In contrast to testosterone, androgen
glucuronides, and specifically androstanediol glucuronide (3α-diol-G), is a measure of the
final breakdown product of all sources of androgens (Mauvais-Jarvis et al., 1970;Moghissi
et al., 1984) and as such may be a measure of total androgen activity in the body. As much
as 40% of total androgens are thought to be produced and used locally without circulating as
serum testosterone (Labrie et al., 2009). Until recently most interest in androgens has
focused on serum testosterone. However, successful treatment of ‘hormone-resistant’
prostate cancer (Fizazi et al., 2012;Scher et al., 2012) with anti-androgens at castrate levels
of serum testosterone (Labrie et al., 2009) has changed thinking about testosterone and refocused attention on the role of total androgen activity in prostate cancer (Auchus and
Auchus, 2012). However, these new insights, suggesting testosterone is more a measure of
gonadal production and androstanediol glucuronide (3α-diol-G) is more a measure of
androgen activity may have general relevance to understanding the role of androgens in
health. No previous studies examining the association of androstanediol glucuronide (3αdiol-G) with markers of the low-grade systemic inflammation, which characterizes many
chronic diseases, in humans could be identified. To clarify the role of androgens in
inflammation among men, this study takes advantage of a nationally representative US
sample, where these androgen biomarkers were assayed for a subset of men, to assess the
relation of these two different androgen biomarkers with markers of low-grade systemic
inflammation..

MATERIALS AND METHODS
Sources of data
The National Health and Nutrition Examination Survey (NHANES) III was conducted from
1988 through 1994 by the National Center for Health Statistics of the Centers for Disease
Control and Prevention (CDC). The NHANES III survey used complex, multi-stage,
stratified, clustered samples of civilian, non-institutionalized populations of age 2 months or
older to collect information about the health of people residing in the US. The participants
were randomly assigned to a physical examination in the morning, afternoon or evening.
During the physical examination blood was taken and analyzed for a range of inflammatory
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markers, including CRP, white blood cell count and its differentials and fibrinogen. Of the
2,205 males aged at least 12 years who participated in NHANES III phase 1 (1988 to 1991)
and attended a morning examination session, 1,637 had surplus sera, previously stored at
−70°C, assayed for sex-steroids using competitive electrochemiluminescence immunoassays
on the 2010 Elecsys autoanalyzer (Roche Diagnostics, Indianapolis, IN) for serum
testosterone, estradiol, and sex hormone binding globulin and an enzyme immunoassay
(Diagnostic Systems Laboratories, Webster, TX) for androstanediol glucuronide (3-alphadiol-G) (AAG), as previously described (Selvin et al., 2007). NHANES III was approved by
the CDC Institutional Review Board and all participants provided written informed consent.
Exposures
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The primary exposures were the androgen biomarkers serum testosterone and AAG. Initial
analysis revealed that considering these exposures log transformed or in their original units
gave a similar interpretation, so for ease of interpretability and comparability the exposures
were considered as z-scores (i.e., standard deviations) of their original units. To allow for
any potentially non-linear associations the exposures were also considered in tertiles, as low
(≤4.34 ng/mL), medium (4.34ng/mL-≤6.04ng/mL) and high (>6.04ng/mL) testosterone and
low (≤8.33 ng/mL), medium (8.33ng/mL-≤13.82ng/mL) and high (>13.82ng/mL) AAG.
Outcomes
The markers of low-grade systemic inflammation considered were CRP, white blood cell
count and its differentials (lymphocytes and granulocytes) and fibrinogen (Lowe, 2005).
Fibrinogen was only assayed for those aged 40 years or older.
Control outcome
Hemoglobin was included as a control outcome because hemoglobin is raised by
testosterone therapy (Fernandez-Balsells et al., 2010), and hemoglobin rises at puberty
among boys in response to rising androgens (Hero et al., 2005). So, a biomarker capturing
androgen activity would be expected to be associated with higher hemoglobin.
Exclusions
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Men taking testosterone therapy, GnRH inhibitors or 5alpha reductase inhibitors were not
excluded, because most of these medications were not available or were only just being
introduced into the US at the time of NHANES III phase 1 in 1988-91. Moreover, these
medications may influence androgens but the resulting androgens should have similar
effects on markers of systemic inflammation. However, the study was restricted to adult men
(18+ years) because the relation of androgens with markers of inflammation might be
different during the hormonal changes of puberty.
Statistical analysis
Multivariable linear regression was used to assess the adjusted association of the androgen
biomarkers with markers of systemic inflammation and hemoglobin. Androgens may vary
with age, race/ethnicity, alcohol use and smoking (Allen et al., 2002;Field et al.,1994;Shiels
et al., 2009;Suzuki et al., 2009) and adiposity (Derby et al., 2006). Model 1 adjusted for age
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(continuous) and race/ethnicity, smoking, alcohol use and education, as categorized in Table
1. Androgens may partially operate via altering body composition. Experimental evidence,
to date, indicates that testosterone therapy reduces body fat (Isidori et al., 2005), although
under the influence of androgens during puberty central fat may increase (Brufani et al.,
2009). Conversely, body fat may reduce androgens through aromatization to estrogens (Kley
et al., 1980). So, to assess these pathways model 2 additionally adjusted for body mass index
and waist-hip ratio. All statistical analyses were performed using SAS, allowing for the
effects of the complex sample design on variance estimation in NHANES III and to weight
the sample back to the US population using sample weights for phase 1 participants who had
a morning examination.
This study is an analysis of de-identified publically available data, which does not require
ethics committee approval.

RESULTS
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Of the 1,637 males aged at least 12 years who participated in NHANES III phase 1 (1988 to
1991), attended a morning examination session and had surplus sera, 1,490 were aged at
least 18 years and had values for one or other androgen biomarker. Potential confounders
were available for all men, although inflammatory markers and measures of adiposity were
missing for some men. All available observations were included in the relevant analysis.
Serum testosterone was only weakly positively correlated with AAG (0.13). Table 1 shows
serum testosterone was lower among men who were older, least educated, former smokers,
ex-drinkers and non-Hispanic white. AAG was lower among older men and non-Hispanic
blacks.
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Serum testosterone was negatively associated with white blood cell count, and granulocyte
count (Table 2). High (compared to low) serum testosterone tertile was also associated with
lower CRP (−0.16 mg/dL, 95% confidence interval (CI) −0.29 to −0.02, lower white blood
cell count (−0.55 10−9, 95% CI −0.79 to −0.31), lower lymphocyte count (−0.08 10−9, 95%
CI −0.16 to −0.002) and lower granulocyte count (−0.47 10−9, 95% CI −0.65 to −0.29). All
these associations were attenuated almost to the null by adjustment for adiposity in model 2.
Serum testosterone was not associated with hemoglobin in model 1. In contrast, AAG was
positively associated with fibrinogen after adjustment for adiposity in model 2 (0.06 g/L per
standard deviation AAG, 95% CI 0.002 to 0.11). AAG had no clear association with CRP or
lymphocyte count, and was weakly positively associated with white blood cell count and
granulocyte count, although the confidence intervals included no association. AAG was also
positively associated with hemoglobin in model 1 (0.70 g/L per standard deviation AAG,
95% CI 0.07 to 1.32).

DISCUSSION
Consistent with other observational studies serum testosterone was negatively associated
with some markers of inflammation (Bonithon-Kopp et al., 1988;Brand et al.,
2012;Gannage-Yared et al., 2011;Haring et al., 2012;Kupelian et al., 2010;Laaksonen et al.,
2003;Yang et al., 1993;Zhang et al., 2013). This study adds by considering an additional
Am J Hum Biol. Author manuscript; available in PMC 2014 May 22.
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biomarker of androgen activity, AAG, which was not associated with lower values of any of
the inflammatory markers considered, but was associated with higher fibrinogen as well as
with hemoglobin as would be expected of an androgen.

NIH-PA Author Manuscript

Despite using data from a meticulously executed population representative study, some
limitations do exist. First, serum testosterone is a well-accepted biomarker, whilst AAG is
rarely used and might represent something other than androgen activity, such as liver
function or obesity. However, that does not seem biologically plausible (Labrie et al., 2009).
The positive association of AAG with hemoglobin was unchanged by adjustment for alanine
aminotransferase (data not shown), and the general pattern of associations for AAG was
similar with and without adjustment for adiposity (model 2 compared with model 1 in Table
2). AAG could also be specifically a marker of aging and ill-health rather than of androgen
activity, although AAG had the same relation with hemoglobin as testosterone therapy
(Fernandez-Balsells et al., 2010), suggesting AAG is a measure of androgen activity.
Second, it may appear counter-intuitive that correlated factors (serum testosterone and
AAG) have different associations with the same outcomes; however the correlation was
relatively weak. Third, serum testosterone was measured using competitive
electrochemiluminescence immunoassays rather than the gold-standard liquid
chromatography tandem mass spectrometry. However, any measurement error is, most
likely, non-differential, impairing the precision of the estimates rather than creating a bias.
Fourth, this study was limited to men, because sex hormones were not measured for women
in NHANES III. However, androgens are a more important hormone among men than
women. Fifth, white blood cell count has been used by others as a marker of systemic lowgrade (Lowe, 2005) and is associated prospectively with ischemic heart disease (Madjid and
Willerson, 2011), particularly granulocyte count (Rana et al., 2007), white blood cell count
could reflect general immune activity in response to chronic and infectious diseases.
However, the pattern of associations was fairly consistent across all markers of
inflammation.
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The discrepancy between the associations of serum testosterone and AAG with markers of
inflammation could be because they affect inflammation differently. For example, serum
testosterone might suppress inflammation whilst dihydrotesterone which is metabolized
from testosterone and also captured by AAG might promote inflammation. Interplays of this
nature are very difficult to distinguish and no studies examining them could be identified.
However, both testosterone and dihydrotestosterone operate via the same androgen receptor.
Conversely, it is also possible that systemic inflammation, or its drivers, affect testosterone
and AAG differently, reducing serum testosterone but not AAG. Pro-inflammatory
cytokines inhibit testosterone secretion through their influence on the hypothalamicpituitary-gonadotropic axis (Turnbull and Rivier, 1997;van der Poll et al., 1993). Notably,
the associations of serum testosterone, but not AAG, with inflammatory markers were
changed by adjustment for adiposity, perhaps because adiposity generates inflammation
(Madsen et al., 2008;Welsh et al., 2010), which in turn reduces testosterone production
(Turnbull and Rivier, 1997;van der Poll et al., 1993). However, it also possible that
testosterone, but not AAG, operates by reducing fat which in turn reduces inflammation.
These possibilities are difficult to distinguish in observational studies and RCTs targeting
markers of systemic inflammation rarely assay androgens. Nevertheless, AAG had the
Am J Hum Biol. Author manuscript; available in PMC 2014 May 22.
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association with hemoglobin expected from RCTs whilst testosterone did not, suggesting
perhaps that serum testosterone rather than AAG may be more sensitive to systemic
inflammation or to common causes of systemic inflammation and ill-health. Given these
uncertainties, it would be valuable to assess the role of endogenous testosterone and AAG in
a study design less open to biases, such as Mendelian randomization. To date, no Mendelian
randomization study examining the association of serum testosterone and/or AAG with
markers of systemic inflammation could be identified A recent, small Mendelian
randomization study did not corroborate the usually observed associations of serum
testosterone with healthier values of conventional cardiovascular risk factors (Haring et al.,
2013).
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The findings from this study for AAG, but not serum testosterone, are consistent with the
findings of RCTs testosterone or dihydrotestosterone therapy, where no significant effect on
CRP, white blood cell count or fibrinogen was found, apart from for one trial where CRP
was only reported for about half the participants (Kalinchenko et al., 2010). Just as observed
here for AAG, such therapy produced non-significant increases in CRP (Aversa et al.,
2010;Kapoor et al., 2007;Nakhai Pour et al., 2007;Ng et al., 2002), white blood cell count
(Kalinchenko et al., 2010) and fibrinogen (English et al., 2000). Larger trials, or new
information from completed trials, are needed to determine whether testosterone or
dihyrotestosterone therapy has the positive relation with markers of systemic inflammation,
as indicators of a less well-functioning immune system, which might be expected from a
theoretical life history perspective. Notably such a perspective provides a general
explanation for several diverse observations, by generating the hypothesis that androgens
might generate both low-grade systemic inflammation and cardiovascular disease (Xu et al.,
2013), and thereby an association of such inflammation with cardiovascular disease.
Moreover, clarification of the effects of androgens on components of the immune system
relating to adaptive immunity, such as lymphocytes, and to innate immunity, such as
granulocytes (Munoz-Cruz et al., 2011) might clarify life history trade-offs concerning
general and specific immune processes, given granulocytes contribute to inflammatory
status and adaptive immune response (Kolaczkowska and Kubes, 2013).
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This study is consistent with and extends the evidence to date concerning the associations of
androgen activity with markers of systemic inflammation. It suggests that the negative
association of serum testosterone with markers of systemic inflammation should not
necessarily be interpreted as indicating that testosterone has a beneficial effect on systemic
inflammation, whilst keeping open the possibility that androgens might have detrimental
effects on the immune system among men. As such, this study raises the possibility that
androgens in men rather than protecting against inflammation may be a factor generating
inflammatory processes by suppressing the immune system. Whether these potential actions
are part of, or a marker of, any causal process involved in any major chronic disease remains
to be determined. This study also strongly suggest that observational studies assessing the
role of androgens need to consider other biomarkers complimentary to serum testosterone,
for which inexpensive assays need to be developed.
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Testosterone and androstanediol glucuronide by socio-demographic characteristics among 1,490 men from
NHANES III phase 1 (1988-1991) - unweighted
Testosterone (ng/mL)

Age

Years of formal
education

Race/ethnicity

n

mean

SD

<45 years

735

5.96

1.96

45+ years

735

4.63

1.87

ANOVA
p-value

<0.001

Androstanediol glucuronide
(ng/mL)
n

mean

SD

741

14.5

10.7

739

12.0

12.1

≤8 years

350

4.93

2.12

355

12.2

9.03

9-11 years

259

5.46

1.94

258

13.5

10.4

12 years

399

5.44

2.09

13+ years

462

5.35

1.93

Non-Hispanic black

362

5.67

2.15

364

12.4

8.9

Mexican-American

383

5.50

2.02

388

13.7

11.6

0.002

401

13.0

11.9

466

14.2

13.2

NIH-PA Author Manuscript

Other

56

4.78

2.01

Non-Hispanic white

669

5.01

1.92

56

10.2

5.9

672

13.8

12.9

Smoking
status

Current

462

6.10

Former

479

4.52

2.09

465

12.7

8.1

1.83

484

13.4

14.7

Never

529

5.29

1.88

531

13.6

10.7

Alcohol use

<1/week

214

5.54

2.09

212

15.4

16.8

1-3/week

341

5.68

1.96

342

13.4

8.8

4+/week

302

5.32

2.06

306

12.7

9.1

Ex-drinkers

418

4.79

1.98

423

12.5

11.6

unknown

86

5.48

2.06

86

13.7

14.4

never

109

5.34

1.84

111

13.0

8.8

<0.001

<0.001

<0.001

SD: standard deviation
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ANOVA
p-value

<0.001

0.08

0.04

0.45

0.08
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Hemoglobin
(g/L)

Fibrinogen
(g/L)

Granulocyte
count
(10−9)

Lymphocyte
count
(10−9)

White blood
cell count
(10−9)

C-reactive
protein
(mg/dL)

1443

1396

2

809

2

1

845

1383

2

1

1430

1396

2

1

1443

1396

2

1

1443

1421

2

1

1469

n

1

Model

0.85

−0.89 to 0.92

0.02

−0.13 to 0.05

−0.04

−0.17 to 0.02

−0.07

−0.18 to 0.02

−0.08

−0.29 to −0.13

−0.21

−0.05 to 0.06

0.01

−0.09 to 0.02

−0.04

−0.19 to 0.05

−0.07

−0.37 to −0.14

−0.26

−0.14 to 0.04

−0.05

−0.16 to 0.004

−0.08

95% CI

b

standard
deviation

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

Low

Tertile

1.83

−0.71 to 2.47

0.88

−0.26 to 0.03

−0.12

−0.30 to −0.01

−0.15

−0.24 to 0.16

1.91

−2.01 to 1.97

−0.02

−0.24 to 0.07

−0.09

−0.35 to 0.01

−0.17

−0.39 to 0.10

−0.14

−0.65 to −0.29

−0.40 to 0.07
−0.04

−0.47

−0.05 to 0.11

0.03

−0.16 to −0.002

−0.08

−0.38 to 0.20

−0.17

−0.06 to 0.11

0.03

−0.11 to 0.08

−0.01

−0.21 to 0.24

−0.09

−0.79 to −0.31

−0.45 to 0.11
0.01

−0.55

−0.24 to 0.03

−0.10

−0.29 to −0.02

−0.16

95% CI

b

High

−0.17

−0.07 to 0.13

0.03

−0.09 to 0.12

0.01

95% CI

b

Medium

Testosterone

1407

1453

816

851

1394

1440

1407

1453

1407

1453

1432

1479

n

0.61

0.07 to 1.32

0.70

0.002 to 0.11

0.06

−0.004 to 0.11

0.05

−0.02 to 0.26

0.12

−0.02 to 0.25

0.12

−0.05 to 0.02

−0.02

−0.05 to 0.02

−0.01

−0.06 to 0.25

0.10

−0.05 to 0.25

0.10

−0.05 to 0.04

−0.004

−0.05 to 0.04

−0.003

95% CI

b

standard
deviation

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

Low

1.58

0.50 to 3.14

1.82

−0.19 to 0.22

0.01

−0.16 to 0.24

0.04

−0.39 to 0.44

0.02

−0.32 to 0.54

0.11

−0.11 to 0.11

−0.001

−0.10 to 0.13

0.02

−0.42 to 0.50

0.04

−0.32 to 0.62

0.15

−0.05 to 0.23

0.09

−0.04 to 0.25

0.10

95% CI

b

Medium

Tertile

Androstanediol glucuronide

1.51

0.27 to 3.55

1.91

−0.17 to 0.23

0.03

−0.15 to 0.24

0.05

−0.32 to 0.53

0.11

−0.27 to 0.60

0.15

−0.09 to 0.15

0.03

−0.07 to 0.18

0.05

−0.32 to 0.63

0.15

−0.25 to 0.70

0.22

−0.10 to 0.10

0.001

−0.08 to 0.11

0.02

95% CI

b

High

Adjusted association of standard deviations of testosterone and androstanediol glucuronide with inflammatory markers among 1,490 men from NHANES
III phase 1 (1988-1991).

NIH-PA Author Manuscript

Table 2
Schooling
Page 13

n

Tertile

b
95% CI
0.27 to 3.40

b

0.07 to 1.63

Medium

95% CI

Low

Model 2 additionally adjusted for body mass index and waist-hip ratio

Model 1 adjusted for age, education, race/ethnicity, smoking and alcohol use

Model

NIH-PA Author Manuscript
standard
deviation

0.11 to 3.72

95% CI

b

High
n

NIH-PA Author Manuscript
Tertile

0.34 to 2.81

−0.07 to 1.29

b

Medium

95% CI

Low

95% CI

b

standard
deviation

Androstanediol glucuronide

−0.08 to 3.10

95% CI

b

High
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